Targeting intracellular signaling pathways to treat rheumatoid arthritis: Pandora's box?

Joint Bone Spine

Volumn 77, Issue 2, 2010, Pages 96-98

  Wendling, Daniel ^a   Prati, Clément ^b   Toussirot, Éric ^a   Herbein, Georges ^c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Intracellular signaling peptides and proteins; Rheumatoid arthritis; Treatment

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAMAPIMOD; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE SYK; R 788; UNCLASSIFIED DRUG; VX 702;

CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ACTIVITY; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LIVER CELL DAMAGE; NAUSEA; NEUTROPENIA; NONHUMAN; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; SIGNAL TRANSDUCTION;

EID: 77949571528     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.01.004     Document Type: Editorial

References (19)

1. Morel J., and Berenbaum F. Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71 (2004) 503-510
2. Sweeney S.E., and Firestein G.S. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 16 (2004) 231-237
3. Simmonds R.E., and Foxwell B.M. NF-kB and its relevance to arthritis and inflammation. Rheumatology 47 (2008) 584-590
4. Roman-Blas J.A., and Jimenez S.A. NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14 (2006) 839-848
5. Schett G., Zwerina J., and Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67 (2008) 909-916
6. O'Shea J.J., and Murray P.J. Cytokine signaling modules in inflammatory responses. Immunity 28 (2008) 477-487
7. Berton G., Mocsai A., and Lowell C.A. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 26 (2005) 208-214
8. Dichamp I., Bourgeois A., Dirand C., et al. Increased nuclear factor-kB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-α. J Rheumatol 34 (2007) 1976-1983
9. Clohisy J.C., Roy B.C., Biondo C., et al. Direct inhibition of NF-kB blocks bone erosion associated with inflammatory arthritis. J Immunol 171 (2003) 5547-5553
10. Weisman M., Furst D., Schiff M., et al. A double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in patients with rheumatoid arthritis. Ann Rheum Dis 61 (2002) 166
11. Damjanov N., Kauffman R.S., and Spencer-Green G.T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60 (2009) 1232-1241
12. Cohen S.B., Cheng T.T., Chindalore V., et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60 (2009) 335-344
13. Kremer J., Bloom B.J., Breedveld F.C., et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis. Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60 (2009) 1895-1905
14. Weinblatt M.E., Kavanaugh A., Burgos-Vargas R., et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor. A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58 (2008) 3309-3318
15. Kaminska B. MAPK signaling pathways as molecular targets for anti-inflammatory therapy. From molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754 (2005) 253-262
16. Sweeney S.E., and Firestein G.S. Mitogen activated protein kinase inhibitors: where are we now and where are we going?. Ann Rheum Dis 65 Suppl. 3 (2006) 83-88 [iii]
17. Mahlknecht U., Will J., Varin A., et al. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 173 (2004) 3979-3990
18. Vallabhapurapu S., and Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27 (2009) 693-733
19. Tas S.W., Vervoordeldonk M.J., Hajji N., et al. Local treatment with the selective IkB kinase β inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 8 (2006) R86